Norwegian biotechnology company Hofseth Biocare inked a consulting deal with London-based surgeon Crawford Currie to strengthen internal relations and communications of the company.
The consultant's experience across medical, pharmaceutical and financial services puts him in a position to interpret and contextualize Hofseth Biocare's products and ongoing research and development efforts to potential and current investors.
Currie practiced within the UK's National Health Service (NHS) for several years prior to moving into a more pharmaceutical focus at English-Swedish pharma company AstraZeneca.
The former surgeon also worked as a pharmaceutical stock analysis and researcher at banking and finance company HSBC and New Street Research, before moving onto fund management at global investment firm Millennium Capital.
The consultancy agreement will originally last three years.
Currie indirectly bought 750,000 shares at a price of NOK 6.00 (€0.59/$0.65) per share in the biotech company, through a 6.82 percent shareholding in Bulgarian company Brilliant Invest.